Almost all cancers show the tendency to aggregate in families. Close relatives of a cancer patient can be considered to have increased risk of at least that form of cancer, and perhaps other cancers. The fraction of a cancer that is hereditary (number of hereditary cases/total number of the cancer) varies substantially. On average, the excess sitespecific cancer risk associated with a positive family history is approximately of 2 to 3-fold above the baseline rate (Williams & Strong, 1985; Mulvihill et al., 1977) . Inherited susceptibility accounts for a high proportion of certain rare forms of cancer, such as the MEN (multiple endocrine neoplasia) syndromes (Knudson, 1985) . However, the hereditary fraction is much smaller for cancers due primarily to environmental carcinogens, such as lung cancers.
Among cohorts of individuals exposed to such potent carcinogens as asbestos or ionising radiation, relatively few develop cancer as a consequence (Li, 1988) . In contrast, the risk of cancer development approaches 100% for carriers of certain cancer genes. These cancer genes are among the several hundred single-gene traits that have been associated with cancer development (Mulvihill et al., 1977) . A point mutation in retinoblastoma gene, for example, confers a 90% likelihood of the cancer (Friend et al., 1988) . These carriers often develop multiple lesions in both eyes at unusually early ages, and subsequently second primary cancers of other organs. Despite its rarity, retinoblastoma has been studied as the model of hereditary cancers in humans (Knudson, 1978) .
Studies of the retinoblastoma gene, Rb, have yielded the first human tumour suppressor gene (Cowell & Hoggs, 1992) . Isolation of the gene was made through a series of clinical, cytogenetic and molecular studies. Clinical observations showed that retinoblastoma is inherited in an autosomal dominant pattern with high penetrance. All retinoblastoma patients with a family history of the tumour or with bilateral lesions have the hereditary disorder. Approximately 10% of unilateral tumour non-familial cases also have the hereditary neoplasm due to a new germinal mutation. Among retinoblastoma cases, a few were observed to have severe mental retardation and birth defects such as microcephaly, colobomas of the eye, and hypertelorism. Chromosome banding studies of these patients showed a consistent inborn deletion at chromosome 13ql4. Additional studies showed that isolated retinoblastoma families have constitutional rearrangements that resulted in loss of alleles on chromosome 13q14 (Cavenee, 1983) . Complementary biochemical studies revealed loss of esterase D alleles on chromosome 13q14 in retinoblastoma specimens (Cowell & Hoggs, 1992 (Harbour et al., 1988; Lee et al., 1987 Knudson's studies of retinoblastoma patients yielded his 2-mutation hypothesis. The model provides the conceptual framework for studying rare families aggregates of virtually any cancer to gain new understanding of human carcinogenesis (Knudson, 1983 (Knudson, , 1985 . He proposed that at least two mutations are required to transform a normal cell into a cancer cell. At the molecular level, familial and sporadic (non-familial) forms of a cancer involve the same gene(s). In sporadic cancers, no mutation is inherited and two somatic mutations must occur within one cell. Hereditary cancer is due to a germinal mutation that has been inherited from a parent and propagated in all somatic cells of susceptible family members; a second mutation transforms the cell. The (Huff et al., 1992) . The findings raise the prospect of several heritable Wilms' tumour gene(s) on chromosome 11 and another elsewhere in the genome. It is unclear whether these genes are involved in alternative pathways in the pathogenesis of Wilms' tumour, or represent different steps in its multistage development. The genetic alterations in Wilms' tumour appear more complex than those for retinoblastoma, and may be more relevant to the common cancers in adulthood.
More is known about the genetics of carcinoma of the colon than other cancers in adults, largely due to the work of Vogelstein and his colleagues (Vogelstein et al., 1988 (Vogelstein et al., , 1989 . Colorectal carcinoma develops in nearly all patients with dominantly inherited adenomatous polyposis coli (APC) and Gardner's syndrome (polyposis of the colon and stomach associated with osseous tumours of the jaw, skull and other sites, fibromas of the mesentery and skin, and carcinoma of the ampulla of Vater) (Bodmer et al., 1987) . The frequency of polyposis in the general population is in the order 1 per 10,000 persons. Colon cancers in polyposis gene carriers tend to arise at early ages, occasionally in teenagers and at multiple foci in the bowel. Initial mapping of the APC gene was accomplished through study of a single patient with polyposis, multiple malformations, mental retardation, and a constitutional deletion of chromosome 5ql3-22 (Bodmer et al., 1987) . The APC gene was isolated in 1991 and appears to account for nearly all polyposis cases (Kinzler et al., 1991) . However, inherited APC mutations have not been detected in familial colon cancer without polyposis, suggesting additional hereditary 'colon cancer genes' (Peltomaki et al., 1992) .
Analyses of colon tumour tissue from diverse patients have revealed multiple genetic alterations (Fearon et al., 1990 ). On average, colon carcinomas appear to have deletion of nearly 20% of all alleles in a non-random distribution (Vogelstein et al., 1989) . These include chromosome 5q deletions that span the APC gene and a second colon cancer-associated gene, MCC (missing in colon cancer). Deletions of chromosome 17 involve the p53 tumour suppressor gene, and deletions of chromosome 18 involve the DCC (deleted in colon cancer) gene (Kinzler et al., 1991) . In addition, activating mutations of ras and myc oncogenes have been found in colon cancers.
Epidemiological studies show that a family history of breast cancer is a consistent risk factor for the neoplasm (Sattin et al., 1985) . In affected families, the risk may be transmitted through either parent, and males have been affected in some kindreds. Some breast cancer in families manifest an autosomal dominant pattern with high penetrance. Patients at highest risk have a family history of premenopausal, bilateral breast cancer affecting both mother and maternal grandmother, or both mother and sister. Cytogenetic analyses show that breast cancer cells are aneuploid and karyotypes are difficult to interpret. Several chromosome regions show non-random losses, and several oncogenes have been shown to be activated by point mutation (ras) or gene amplification (Her-2/neu). Recently the major gene locus for familial breast cancer and familial breast-ovarian cancer of early onset was mapped to chromosome 17q (Narod et al., 1991) . Intensive efforts are under way to isolate this important breast cancer gene.
Another common form of cancer in industrialised nations, carcinoma of the prostate, displays a similar familial tendency. A recent hospital-based study of male relatives of 691 consecutive prostate cancer patients showed an odds ratio of 2 for men with an affected first-degree relative or second-degree relative, and 8.8 for those with both an affected first-and second-degree relative (Steinberg et al., 1990; Carter et al., 1992) . The risk increases with the total number of affected family members. Familial prostate cancer also tends to occur at early ages, and accounts for a substantial fraction of the disease in younger men. The study supports earlier reports of a familial tendency of prostate cancer, but the location of the gene(s) remains unknown.
Families have been reported with cancers at multiple anatomic sites. Fraumeni and I have described family cancer syndrome of breast cancer in young women and childhood sarcomas and other neoplasms . The syndrome was initially identified in a series of families with an autosomal dominant pattern of these tumours. Prospective follow-up of candidate families was conducted, which showed an excess of the component neoplasms during follow-up observation that appears to be free of ascertainment bias (Garber et al., 1991) . Additional studies of the syndrome revealed an excess of breast cancers among mothers of population-based series of children with sarcoma. Also, segregation analysis of a series of children with soft-tissue sarcoma showed evidence for transmission of a dominant cancer susceptibility gene. To date at least seven component cancers of the syndrome have been reported: breast cancer, soft tissue sarcoma, osteosarcoma, acute leukaemia, brain tumours, adrenocortical carcinoma, and gonadal germ cell tumours. The possibility exists of other component neoplasms which tend to occur at early ages. In 1990, a search for germ line mutations in known tumour suppressor genes among these families revealed point mutations in the p53 genes in five affected kindreds (Malkin et al., 1990) . As in the retinoblastoma paradigm, tumour specimens from these patients showed loss of the second wild-type (normal) allele. The mutations tend to be localised in the evolutionary conserved portions of the gene. There are families with LiFraumeni syndrome that do not appear to have any germinal p53 mutations. It is uncertain whether the finding is due to undetected p53 mutations or to genetic heterogeneity. In addition, rare patients have been reported with germ line p53 mutations but not a family history of the syndrome (Malkin et al., 1992) . These patients raise the possibility that penetrance of the germ line mutation might be lower than that reported previously .
Caution is needed to avoid pitfalls in studies of the molecular epidemiology of familial cancers, which can also be due to shared environmental influences. or chance association (Li, 1988) . The distinction between inherited susceptibility and chance association can be particularly difficult in families with common forms of cancer, such as carcinomas of the breast and colon. One person in three in the United States and other industrialised nations develops an internal malignant neoplasm within the course of a lifetime. The lifetime cancer risk is one in two when carcinomas of the skin are included in the analysis. The 240 million persons in the US will form many striking family aggregates of cancer by chance. A family history of cancer is, therefore, the rule and not the exception. Several clinical features have been described in hereditary cancers: specificity of the cancers by organ site or tissue of origin, earlier age of occurrence than is usual for that neoplasm, multifocal cancers of polyclonal origin within the susceptible organ, and development of multiple primary cancers in individual patients. Unfortunately, these findings are not highly specific indicators of genetic predisposition (Schneider et al., 1986) .
